SELLAS Life Sciences (SLS) Convertible Debt (2012 - 2016)
SELLAS Life Sciences (SLS) reported Convertible Debt of $5.7 million for Q4 2016, up 465.9% on a QoQ basis from $1.0 million in Q1 2012.
SELLAS Life Sciences (SLS) has 2 years of Convertible Debt data on file, last reported at $5.7 million in Q4 2016.
- Quarterly Convertible Debt changed N/A year-over-year to $5.7 million in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $5.7 million (changed N/A YoY) and the FY2016 annual result came in at $5.7 million, changed N/A from the prior year.
- Convertible Debt climbed to $5.7 million in Q4 2016 per SLS's latest filing, from $1.0 million in the prior quarter.
- Across five years, Convertible Debt topped out at $5.7 million in Q4 2016 and bottomed at $1.0 million in Q1 2012.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 5.66 Mn |
| Mar 31, 2012 | 1.00 Mn |